If you liked this article you might like

Hep C Business Slow-Down Could Hamper Bristol-Myers' Future

Hep C Business Slow-Down Could Hamper Bristol-Myers' Future

Jim Cramer Says Oncology Drug Franchises Helping Both Celgene and Bristol-Myers

Jim Cramer Says Oncology Drug Franchises Helping Both Celgene and Bristol-Myers

Bristol-Myers (BMY) Stock Slides Despite Q2 Earnings, Revenue Beat

Bristol-Myers (BMY) Stock Slides Despite Q2 Earnings, Revenue Beat

3 Stocks Dragging The Health Care Sector Downward

3 Stocks Dragging The Health Care Sector Downward